Maravai LifeSciences (MRVI) Competitors $2.10 -0.11 (-4.98%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$2.17 +0.07 (+3.33%) As of 04/3/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. NAMS, VCEL, MIRM, RXRX, BLTE, EWTX, DNLI, TARS, BEAM, and AAPGShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include NewAmsterdam Pharma (NAMS), Vericel (VCEL), Mirum Pharmaceuticals (MIRM), Recursion Pharmaceuticals (RXRX), Belite Bio (BLTE), Edgewise Therapeutics (EWTX), Denali Therapeutics (DNLI), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. NewAmsterdam Pharma Vericel Mirum Pharmaceuticals Recursion Pharmaceuticals Belite Bio Edgewise Therapeutics Denali Therapeutics Tarsus Pharmaceuticals Beam Therapeutics Ascentage Pharma Group International NewAmsterdam Pharma (NASDAQ:NAMS) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do insiders and institutionals have more ownership in NAMS or MRVI? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 0.6% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend NAMS or MRVI? NewAmsterdam Pharma currently has a consensus target price of $43.33, indicating a potential upside of 140.74%. Maravai LifeSciences has a consensus target price of $7.31, indicating a potential upside of 247.88%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media prefer NAMS or MRVI? In the previous week, Maravai LifeSciences had 15 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 31 mentions for Maravai LifeSciences and 16 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.83 beat Maravai LifeSciences' score of 0.06 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 2 Very Positive mention(s) 2 Positive mention(s) 25 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is NAMS or MRVI more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. NewAmsterdam Pharma's return on equity of 0.00% beat Maravai LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Maravai LifeSciences -81.13%-6.61%-3.45% Which has higher valuation and earnings, NAMS or MRVI? Maravai LifeSciences has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M43.38-$176.94M-$2.60-6.92Maravai LifeSciences$259.19M2.06-$119.03M-$1.02-2.06 Which has more volatility and risk, NAMS or MRVI? NewAmsterdam Pharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Does the MarketBeat Community favor NAMS or MRVI? Maravai LifeSciences received 37 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.30% of users gave NewAmsterdam Pharma an outperform vote while only 60.00% of users gave Maravai LifeSciences an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes2696.30% Underperform Votes13.70%Maravai LifeSciencesOutperform Votes6360.00% Underperform Votes4240.00% SummaryNewAmsterdam Pharma beats Maravai LifeSciences on 11 of the 18 factors compared between the two stocks. Remove Ads Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$534.11M$6.73B$5.54B$7.50BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-1.286.9923.2218.08Price / Sales2.06198.60363.5486.83Price / Cash41.7165.6738.1634.64Price / Book0.675.926.513.99Net Income-$119.03M$142.37M$3.21B$247.18M7 Day Performance-11.02%-7.24%-4.88%-4.25%1 Month Performance-26.06%-10.45%-0.06%-6.87%1 Year Performance-75.35%-14.58%6.62%-3.73% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences4.5344 of 5 stars$2.10-5.0%$7.31+247.9%-75.6%$534.11M$259.19M-1.28610Options VolumeGap DownNAMSNewAmsterdam Pharma2.5106 of 5 stars$20.47-5.9%$43.33+111.7%-18.6%$2.25B$45.56M-7.874Gap DownVCELVericel3.0801 of 5 stars$44.62+0.3%$62.29+39.6%-15.3%$2.24B$237.22M743.79300Positive NewsGap DownMIRMMirum Pharmaceuticals4.3193 of 5 stars$45.05-2.0%$58.20+29.2%+74.7%$2.21B$336.89M-22.30140Positive NewsRXRXRecursion Pharmaceuticals2.2625 of 5 stars$5.29-9.0%$8.25+56.0%-46.1%$2.13B$58.49M-3.46400Gap DownBLTEBelite Bio1.9601 of 5 stars$66.22-0.7%$96.67+46.0%+58.8%$2.11BN/A-59.6610EWTXEdgewise Therapeutics1.8405 of 5 stars$22.00-5.5%$45.38+106.3%-26.6%$2.09BN/A-14.6760Analyst ForecastOptions VolumeNews CoverageGap DownDNLIDenali Therapeutics4.1925 of 5 stars$13.60-8.0%$37.20+173.5%-34.0%$1.97B$330.53M-4.93430News CoverageGap DownHigh Trading VolumeTARSTarsus Pharmaceuticals2.696 of 5 stars$51.37-0.7%$63.67+23.9%+38.1%$1.97B$182.95M-13.4850Positive NewsGap DownBEAMBeam Therapeutics3.1171 of 5 stars$19.53-12.1%$49.45+153.2%-44.5%$1.95B$63.52M-11.10510Insider TradeShort Interest ↑Gap DownHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$21.95+1.4%N/AN/A$1.91B$980.65M0.00600News Coverage Remove Ads Related Companies and Tools Related Companies NAMS Alternatives VCEL Alternatives MIRM Alternatives RXRX Alternatives BLTE Alternatives EWTX Alternatives DNLI Alternatives TARS Alternatives BEAM Alternatives AAPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
